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ORIGINAL ARTICLE
Digital rectal examination (DRE) is an established
and important part of a patient’s physical exami-
nation by both urologists and general physicians
in evaluating prostate and rectal problems. With
the use of systemic random prostate biopsy and
the development of prostate specific antigen
(PSA) testing, the importance of DRE is no longer
emphasized as much as before in detection of
prostate cancer. In determining histological pro-
gression of prostate lesions, transrectal ultrasound
(TRUS) is an advance over traditional purely 
digital guided biopsy. TRUS provides real-time
monitoring of biopsy tracts and random sampling
of the prostate lesions that cannot be visualized
and that are nonpalpable.1 In 1989, Hodge et al
originally proposed the concept of random sys-
temic sextant prostate biopsy, which minimizes
observer and sampling errors with lesion-directed
biopsy.2 Later, several studies found an improve-
ment in prostate cancer detection with extended-
core TRUS-guided prostate biopsy protocols.
Initially, 10- to 12-core prostate biopsies were
suggested by most investigators.3 Recently, some
studies have even recommended a 21-core prostate
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Background/Purpose: The purpose of this study was to compare prostate cancer detection rates and
pathology results, using the Gleason grading system, of 12-core systemic random transrectal ultrasound-
guided prostate biopsy (SB) and 3-core finger-guided prostate nodule biopsy (FGNB).
Methods: Between January 2002 and December 2006, 148 patients with digitally palpable prostate nodules
received SB and additional FGNB. The prostate cancer detection rates and Gleason scores of positive can-
cer specimens were compared between SB and combination biopsy (SB + FGNB). The patients’ characteristics,
including age, prostate specific antigen (PSA), percentage of free PSA and prostate volume were also recorded.
Results: With simple SB, FGNB, and combination biopsy, the prostate cancer detection rates were 39.9%,
37.9%, and 44.6%, respectively. Of the 66 patients with prostate cancer, the Gleason sum was underesti-
mated in three patients with simple SB only and in one patient with FGNB only. The false-negative rates for
SB and FGNB were 10.6% and 15.2%, respectively.
Conclusion: In patients with a palpable prostate nodule, combination biopsy with systemic and nodule
biopsy could avoid some misdiagnoses of prostate cancer and provide more accurate information for
pathology grading. [J Formos Med Assoc 2009;108(9):713–718]
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biopsy protocol to provide early diagnostic and
prognostic value in patients with prostate cancer.4
However, it has been questioned whether 
systemic random prostate biopsy without lesion-
guided sampling was sufficient for all patients
suspected of having prostate cancer. Some studies
have documented the importance of additional
lesion-guided biopsies with positive ultrasound
findings or positive DRE.5–7 In this article, the 12-
core systemic biopsy together with a 3-core finger-
guided nodule biopsy (FGNB) is defined as
combination biopsy. This study aimed to present
a retrospective analysis of combination biopsy to
survey whether the proposed strategy would
yield a higher prostate cancer detection rate.
Methods
Between January 2002 and December 2006, 148
patients with digitally palpable prostate nodules
underwent systemic random 12-core TRUS-guided
prostate biopsy (SB) with additional 3-core FGNB
at the National Taiwan University Hospital. The
indication for biopsy was a positive DRE diagno-
sis noted by a single physician. All patients gave
their informed consent.
Rectal preparation with bisacodyl was per-
formed 6 hours before biopsy. Patients taking
antiplatelet/anticoagulation agents were instructed
to discontinue aspirin 7 days before biopsy and
to discontinue warfarin 3 days before biopsy.
Between January 2002 and December 2004, pa-
tients received pipemidic acid 500 mg twice daily
for 3 days starting from the day of biopsy. In the
period from January 2005 to December 2006,
patients received a single dose of levofloxacin
(500 mg) in the morning before biopsy.
TRUS examinations were performed with a
real-time ultrasound scanner (Model 1846; 
Brüel & Kjær Sound & Vibration Measurement A/S,
Nærum, Denmark) using a 7-MHz transducer.
Prostate volume was calculated from the TRUS
image using the formula: volume (cm3) = 0.52 ×
length×width×height (cm). Patients were placed in
the left decubitus position. Biopsies were done with
18G tru-cut biopsy needles during longitudinal
scanning.
Concerning the sequence, FGNB was per-
formed first. Each nodule biopsy included three
biopsy cores. Then, SB, standard sextant biopsy
with an extra three cores taken from each side of
the more lateral prostate areas, including the base,
midlobe, and apex was performed. The combi-
nation biopsy left lateral (LL), left medial (LM),
right medial (RM), right lateral (RL), and nodule
specimens were placed in five respectively la-
beled containers. All specimens were fixed in 
formalin and evaluated according to the Gleason
grading system. Prostate cancer detection rates
and Gleason scores of positive cancer specimens
were compared between SB, FGNB, and combi-
nation biopsy (SB + FGNB). The patients’ charac-
teristics, including age, PSA, percentage of free
PSA and prostate volume were also recorded.
Data were analyzed using MedCalc version
9.3.0.0 (MedCalc Software, Mariakerke, Belgium)
for Windows. The χ2 test was used to compare
categorical variables. Dependent continuous vari-
ables were analyzed with ANOVA and the paired
t test. For all tests, a p value < 0.05 was regarded
as significant.
Results
Of the 148 patients, 66 (44.6%) patients had
prostate cancer detected. The prostate cancer de-
tection rates for SB, FGNB, and combination
biopsy were 39.9%, 37.9%, and 44.6%, respec-
tively. Positive pathology findings for 49 patients
were detected in both SB and FGNB specimens.
Positive pathology findings were detected in the
FGNB specimens of only seven patients, and in
the SB specimens of only 10 patients. Although
combination biopsy yielded a higher overall pros-
tate detection rate than FGNB (p = 0.410) and SB
(p = 0.238) alone, the difference was not statisti-
cally significant. The clinical characteristics in-
cluding age, prostate volume, PSA, and percentage
of free PSA were not significantly different be-
tween patients with prostate cancer diagnosed by
I.N. Chiang, et al
714 J Formos Med Assoc | 2009 • Vol 108 • No 9
FGNB alone, by SB alone, or by combination
biopsy (Table 1). Of the 148 patients, 63 (42.6%)
patients were noted to have suspicious prostate
hypoechoic lesions on TRUS. There was no sta-
tistically significant difference in prostate detec-
tion rates between patients with and without
TRUS findings, 36.5% versus 50.6% (p = 0.088).
The pathology results of both SB and FGNB
specimens from patients with prostate adenocar-
cinoma according to the Gleason grading system
were analyzed. Overall, there were 66 patients
with prostate cancer. In the combination biopsy
specimens, each of the three cores of prostate tis-
sue from the five different portions of the prostate
was defined as a single specimen. Overall, 203
specimens had prostate adenocarcinoma detected
out of 330 specimens from 66 men with prostate
cancer. Of these, 147 specimens with cancer were
obtained from SB, and 56 specimens with cancer
were obtained from FGNB. The positive rates of
specimens obtained from FGNB and SB were
considered as an index of the sensitivity of these
two biopsy methods. In this study, for the patients
with prostate cancer, the positive pathology rate
of FGNB specimens was significantly higher 
than the positive pathology rate of SB specimens
(84.8% vs. 54.7%; p < 0.001). Mean Gleason
scores, which were 7.25 ± 1.13 and 7.21 ± 1.04
for FGNB and SB respectively, showed no signifi-
cant difference (p = 0.858). Overall, the propor-
tion of Gleason sum ≥ 7 accounted for 80.3% of
the patients with prostate cancer. The specimens
obtained from FGNB had a higher proportion of
Gleason sums ≥ 7 in comparison with SB (83.9%
vs. 76.7%; p = 0.262). The Gleason sum was un-
derestimated in three patients with SB alone and
in one patient with FGNB alone. As for clinical
staging, 47 (71.2%) patients were T2, 15 (22.6%)
patients were T3, and four (6.2%) patients were
T4. Eleven (16.7%) patients were noted to have
distant metastasis. They had a significantly higher
Gleason sum (8.00 vs. 7.04; p = 0.004) and higher
serum PSA (105.8ng/mL vs. 19.1ng/mL; p<0.001).
Prostate cancer was detected in both SB and
FGNB specimens.
There was no significant difference in positive
pathology rates and Gleason scores of specimens
from the LL, LM, RM and RL aspects of the
prostate. The lateral portions of the prostate did
not yield significantly higher positive biopsy rates
than the medial portions (56.8% vs. 54.5%;
p = 0.711) (Table 2). In our study, SB specimens
were divided into the ipsilateral side and contralat-
eral side of the palpable nodule. SB specimens
from the ipsilateral side of the prostate nodule
had a significantly higher positive pathology rate
than did specimens from the contralateral side
(67.4% vs. 43.1%; p = 0.001).
To evaluate the safety of the 15-core combi-
nation biopsy, we also recorded any major com-
plications after biopsy, defined as complications
requiring readmission or an emergency room
visit. Of the 148 patients, nine (6.1%) experi-
enced major postoperative complications, in-
cluding fever, acute urinary retention, and gross
hematuria.
Discussion
In our study, the prostate cancer detection rates,
diagnostic value, and safety of combination biopsy
Combination biopsy in prostate cancer detection
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Table 1. Comparison of clinical characteristics of patients with prostate cancer detected by nodule biopsy
alone (N), systemic biopsy alone (S), and both nodule and systemic biopsy (N + S)
N (n = 7) S (n = 10) N + S (n = 49) Total (n = 66) p
Age (yr) 74.14 ± 4.56 71.50 ± 11.23 69.96 ± 7.71 70.64 ± 8.07 0.417
Prostate volume (mL) 35.07 ± 15.34 35.57 ± 3.35 41.05 ± 22.93 39.82 ± 20.24 0.886
PSA (ng/mL) 26.71 ± 28.14 11.91 ± 4.84 39.68 ± 84.34 34.27 ± 73.88 0.570
Free PSA (%) 3.50 ± 2.88 9.67 ± 9.27 9.40 ± 8.52 8.83 ± 8.25 0.359
PSA = prostate specific antigen.
with SB and FGNB were evaluated. It was found
that additional FGNB improved the prostate 
cancer detection rate by 4.7%. Reducing the false-
negative rate of prostate biopsy will avoid repeat
biopsy and optimize early detection and treat-
ment planning for patients with prostate cancer.
DRE is suggested for men older than 40 years
old and for men of any age who have genitouri-
nary symptoms. It is probably the most common
physical examination in the urological clinic, but
it may be the most unpleasant part of a physical
examination because of patients’ embarrassment
and discomfort. DRE is utilized in the detection
of prostate and rectal diseases, including benign
prostate hyperplasia, acute prostatitis, prostate
cancer, hemorrhoids, rectal cancer, rectal polyps,
anal fistula and fissures.8 With the development
of PSA measurement, TRUS, computed tomogra-
phy, and endorectal magnetic resonance imag-
ing,9 there are many novel tools for prostate cancer
detection. There have been studies discussing the
role of DRE in the early detection of prostate
cancer. Schroder et al claimed that for patients
with low PSA values (0–3.9 ng/mL), the positive-
predictive value and sensitivity of DRE, tumor
volume, and tumor grade are strongly dependent
on PSA level, and that DRE does not perform
well.8 Philip et al reviewed 12-core prostate biopsy
results, DREs and the pathology presentations of
radical prostatectomy specimens from 408 pa-
tients with PSA of 2.5–10 ng/mL.10 They found
that the prostate cancer detection rates were 47%
in patients with abnormal DRE (which is similar
to our findings) and 27% in patients with nor-
mal DRE, but almost 40% of the patients with
prostate cancer stage T2 to T4 had a normal DRE.
In our study, it was found that 44.6% of 148
patients with palpable nodules were diagnosed
with prostate cancer. In our previous study, the
prostate cancer detection rate in 1875 patients
with elevated PSA, with or without palpable nod-
ules, was 28.5%.11 There have also been some
studies recognizing the diagnostic value of DRE.
In 1987, Guinan et al compared five tests used in
the diagnosis of prostate cancer which, in de-
creasing order of accuracy, were DRE, PSA, TRUS,
acid phosphatase and, finally, aspiration cytol-
ogy.12 Sheikh et al conducted a study to determine
the usefulness of DRE, TRUS and serum PSA in
the diagnosis of prostate cancer in Arab men.13
They found that DRE(+) tripled the probability
of cancer detection, while TRUS was only signifi-
cantly associated with detection of cancer if PSA
was elevated. Roobol et al evaluated the value of
screening tests in identifying men with an ele-
vated risk of having prostate cancer and the dif-
ferences between three centers in the European
Randomised study of Screening for Prostate 
Cancer (ERSPC) with 2483 patients, and found
that the predictive values of DRE and TRUS 
varied considerably among the three centers.14 In
Australia, Huynh et al found that FGNB, in addi-
tion to SB, in patients with palpable prostate nod-
ules could increase the prostate cancer detection
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Table 2. Comparisons of positive pathology rates and Gleason scores between specimens from different prostate portions:
left lateral (LL), right lateral (RL), left medial (LM), right medial (RM), and nodule (N)
LL RL LM RM N Total p
Specimens (n) 38 37 35 37 56 203
Positive rate (%) 57.6 56.1 53.0 56.1 84.8 61.5 < 0.001
Gleason score 7.17 ± 0.96 7.19 ± 0.85 7.17 ± 7.19 7.32 ± 1.08 7.25 ± 1.13 7.22 ± 1.06 0.972
Lateral specimens Medial specimens N
Positive rate (%) 56.8 54.5 84.8 < 0.001
Gleason score 7.18 ± 0.95 7.25 ± 1.13 7.25 ± 1.13 0.917
Systemic biopsy specimens N
Positive rate (%) 55.7 84.8 < 0.001
Gleason score 7.21 ± 1.04 7.25 ± 1.13 0.858
rate from 47.9% to 55.4%.5 Furthermore, Mancuso
et al demonstrated that, of 500 men with a pal-
pable prostate nodule over 6 years, 14.6% were
diagnosed with prostate cancer using FGNB
only.6 In our study, FGNB increased the prostate
detection rate from 39.9% to 44.6%.
DRE techniques are explained in detail in
most textbooks in the fields of physical examina-
tion and urology, as Marshall described.15 In our
study, the insertion of an adequately lubricated,
slow, steady, slightly-circling single digit, as well
as an explanation of the possible voiding or defe-
cation desires can decrease patient discomfort.
As for the technique of FGNB, the importance of
the biopsy sequence has to be strongly empha-
sized. FGNB should be performed before SB. If
SB is performed first, swollen prostate tissue will
mask the digital sensation of the prostate nodule.
In our study, a trumpet-like biopsy guide device
was used for FGNB, as in the procedure described
by Woo et al.16 For the physicians’ safety, the fin-
gers should always be kept behind the tip of the
biopsy guide.
In the early 1990s, there were several studies
comparing the diagnostic values of ultrasound-
guided and traditional digital-guided prostate
biopsy. Van Every and Rooney found that the two
methods were comparable in terms of prostate
cancer detection.17 In Türkeri et al’s study of 40
patients with palpable prostate nodules, they 
compared the efficacy of digital- and ultrasound-
guided prostate biopsies,18 and found 10 patients
with normal TRUS findings. Systemic biopsy re-
vealed 21 patients with prostate cancer, while
digitally-guided prostate biopsy yielded only 
18 patients with prostate cancer. The authors
concluded that systemic biopsies are necessary
regardless of TRUS findings, and that digitally-
guided biopsies are unnecessary. Lan et al dis-
cussed the controversial issue of lesion-guided
biopsy by evaluating the diagnostic performance
of random versus lesion-guided biopsy of the
prostate, based on TRUS.19 In this study, although
the cancer detection rate of lesion-directed TRUS
biopsy was superior to that of random biopsy, 
in some cases prostate cancer was diagnosed in
sonographically normal images, appearing in half
of the prostates.19 Thus, systemic random biopsy
is mandatory.
Palpable prostate nodules may present with
normal TRUS images, and there are varied TRUS
presentations of prostate cancer. The digitally 
lesion-guided prostate biopsy can compensate
for the insufficiency of TRUS lesion-guided biopsy
in patients with palpable nodules and normal or
equivocal ultrasound images. In our study, it was
found that combination biopsy can avoid some
false-negatives with SB or FGNB, but FGNB spec-
imens did not show significantly higher histol-
ogy grading than SB specimens. An abnormal
DRE has been shown to be an independent pre-
dictor for prostate cancer and was associated
with a Gleason sum ≥ 7 in multivariate analysis.20
Also, it was noted that in patients with abnormal
DRE, the specimens obtained from FGNB had a
higher proportion of Gleason sums ≥ 7. Although
the increase did not reach statistical significance,
the present study could not neglect the benefits
of FGNB. Without FGNB in addition to SB, the
Gleason sum of three patients would have been
underestimated, and seven patients would have
been misdiagnosed. In our study, with simple SB
and simple FGNB, the false-negative rates were
10.6% and 15.2%, respectively. It could be hy-
pothesized that SB would detect lesions that 
are too small to be visualized and palpated, and
FGNB would increase the cancer detection rate
by avoiding misdiagnosis as a result of random
sampling. In this study, conducted on 148 pa-
tients with palpable prostate nodules, combina-
tion biopsy yielded the highest cancer detection
rate. Previous studies documented the clinical sig-
nificance of TRUS lesion-guided prostate biopsy.19
In our study, no additional TRUS lesion-guided
biopsy on these patients was performed because,
after FGNB, the TRUS images were confusing.
As for complications following prostate biopsy,
several studies have documented the safety of in-
creasing the number of prostate biopsy cores, i.e.
without increasing complications, for up to 21
cores.4 The major complication rate of 15-core
combnation biopsy in this study was 6.1%. In our
Combination biopsy in prostate cancer detection
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previous study on the complications of prostate
biopsy, there was no significant difference in com-
plication rates among the 6-, 12- and 15-core
groups, which were 6.34%, 6.90% and 6.95%,
respectively.11 Thus, in patients with a palpable
prostate nodule, combination biopsy appears to
be a safe and effective biopsy regimen.
In patients with a palpable prostate nodule,
combination biopsy with systemic versus nodule
biopsy avoids some misdiagnoses of prostate can-
cer and could provide more accurate informa-
tion for pathology grading.
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